Traduction de «informing the patient with regard » (Néerlandais → Français) :

The optimal scenario for informing the patient with regard to decisions related to reimbursement of products linked to a specific treatment is similar to the previous one but (Figure 8) presents a higher number of respondents choosing “inside the organs” and “at each step”. Only 26% would choose to inform the patient outside the existing organs, and with a stronger preference on informing after the decision is taken.
The optimal scenario for informing the patient with regard to decisions related to reimbursement of products linked to a specific treatment is similar to the previous one but ( Figure 8) presents a higher number of respondents choosing “inside the organs” and “at each step”.

As regards schizophrenia, the risk of suicide is greater with male patients in the first stages of the disorder, especially with patients who were particularly dynamic before the disorder started, and with patients who suffer chronic relapses.
En ce qui concerne la schizophrénie, le risque de suicide est plus marqué chez les patients masculins, dans les premiers stades de la maladie, en particulier auprès des patients particulièrement dynamiques avant la déclaration de la maladie, et auprès des patients avec des rechutes chroniques.

The subpoena covered information regarding potential off-label marketing and promotion of TOBI (tobramycin), a treatment for patients with cystic fibrosis acquired through the purchase of Chiron Corporation in mid-2006.
Cette assignation couvrait des informations concernant l’éventualité d’une commercialisation et de promotion de TOBI (tobramycine), un traitement contre la fibrose cystique acquis lors de l’achat de Chiron Corporation à la mi-2006, pour des indications pour lesquelles ce produit n’a pas été autorisé.

The subpoena covered information regarding potential off-label marketing and promotion of TOBI, a treatment for patients with cystic fibrosis acquired through the purchase of Chiron Corporation in mid-2006.
Cette assignation couvrait des informations concernant l’éventualité d’une commercialisation et de promotion de TOBI, un traitement contre la fibrose cystique acquis lors de l'achat de Chiron Corporation à la mi-2006, pour des indications pour lesquelles ce produit n’a pas été autorisé.

8.1 General considerations Communicating data regarding the status of MRSA carriage of a patient must be done in accordance with the protection of confidentiality and patient privacy.
8.1 Considérations générales La communication de données concernant le statut de portage de MRSA des patients doit être réalisée dans le respect de la protection de la confidentialité et de la vie privée du patient.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

The prevention of adverse effects and adverse events attributable to the use of medicines and health products is closely linked with information for healthcare professionals and the public regarding the risks associated with the use of medicines and health products.
The prevention of adverse effects and adverse events attributable to the use of medicines and health products is closely linked with information for healthcare professionals and the public regarding the risks associated with the use of medicines and health products.

In the first scenario, there is no significant difference between the respondents with regard to the choice of the place where the information is given (inside or outside the existing decision-making organs) according their current/past membership (or not) of the INAMI – RIZIV organs.
Only 26% would choose to inform the patient outside the existing organs, and with a stronger preference on informing after the decision is taken. In the first scenario, there is no significant difference between the respondents with regard to the choice of the place where the information is given (inside or outside the existing decision-making organs) according their current/past membership (or not) of the INAMI – RIZIV organs.

To minimise the risk of MRSA transmission by contacts with the patients and their families during transfer between healthcare facilities, it is recommended to provide clear information to the patients and their relatives about the significance of MRSA carriage and the precautions to be taken to limit its dissemination.
Afin de réduire au minimum le risque de transmission de MRSA par les contacts avec les patients ou leur famille au cours du transfert entre les installations des établissements de soins de santé, il est recommandé d’informer clairement le patient et sa famille de la signification du portage de MRSA et des précautions à prendre pour en limiter la dissémination.

The FDA is reviewing Exjade safety information specifically on the risk of adverse events in patients with myelodysplastic syndrome (MDS) compared to patients without these conditions.
La FDA examine les informations concernant l’innocuité d’Exjade en particulier par rapport au risque d’effets secondaires chez les patients atteints du syndrome myélodysplasique (MDS) en comparaison des malades qui en sont indemnes.